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Abstract
Background: Sarcopenia, frailty, cachexia and malnutrition are widespread syndromes in older people, characterized
by loss of body tissue and related to poor outcome. The aim of the present cross-sectional study was to assess the
prevalence of these syndromes and their overlap in older medical inpatients.
Methods: Patients aged 70 years or older who had been admitted to the internal medical department of a German
university hospital were recruited. Sarcopenia, frailty, cachexia and malnutrition were assessed in a standardized
manner according to current consensus definitions. Prevalence rates of these syndromes and their constituents and
the concurrent occurrence of the syndromes (overlap) were calculated.
Results: One hundred patients (48 female) aged 76.5 ± 4.7 years with a BMI of 27.6 ± 5.5 kg/m2 were included. The
main diagnoses were gastroenterological (33%) and oncological diseases (31%). Sarcopenia was present in 42%, frailty
in 33%, cachexia in 32% and malnutrition in 15% of the patients. 63% had at least one syndrome: 32% one, 11% two,
12% three and 8% all four. All four syndromes are characterized by significant weight loss during the last 12months,
which was most pronounced in malnourished patients and least pronounced in frail patients, and by significantly
reduced physical performance. All syndromes were significantly pairwise related, except malnutrition and frailty.
In 19% of patients sarcopenia and frailty occurred concurrently, in 20% frailty and cachexia and in 22% sarcopenia
and cachexia with or without additional other syndromes. All malnourished patients except one were also
cachectic (93%) and 80% of malnourished patients were also sarcopenic. 53% of malnourished patients were in
addition frail, and these patients were affected by all four syndromes.
Conclusions: Nearly two thirds of older medical inpatients had at least one of the tissue loss syndromes sarcopenia,
frailty, cachexia and malnutrition. The syndromes overlapped partly and were interrelated. Future studies with larger
patient groups and longitudinal design are required to clarify the significance of single and concurrent occurrence of
these syndromes for clinical outcome and successful therapy.
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Introduction
Sarcopenia, frailty, cachexia and malnutrition are wide-
spread syndromes in older people and associated with
an increased risk of poor outcome like mobility limita-
tion, fracture, increased length of hospital stay, hospital
readmission, morbidity and mortality [1–4]. In hospital
patients the hazard of these syndromes is particularly
high due to acute illness, immobility and anorexia.
Prevalence rates up to 50% or more have been reported
in older patients for all syndromes [5–8], however, with
great variation between studies, not least due to of
different diagnostic criteria.
One central aspect of all syndromes is the loss of body
tissue [9], which however affects different tissues to a
varying extent. Whereas in sarcopenia, frailty and cach-
exia the loss of fat-free mass, especially skeletal muscle
mass, is crucial [10–12], in malnutrition fat free mass as
well as fat mass are reduced [13]. Besides these changes
in body composition, all syndromes except malnutrition
are characterized by specific additional features: sarcope-
nia and frailty by reduced strength and function [10, 11],
frailty in addition by exhaustion and low physical activity
[11], and cachexia by reduced strength, fatigue, anorexia
and inflammation [12]. All syndromes also share similar
etiological factors which are differently pronounced, i. e.
reduced food intake, inflammation, hormonal changes,
increased energy requirements and reduced physical
activity [9].
Due to these similarities in etiology and definitions, the
syndromes partly overlap and can be present in the same
patient. This concurrent occurrence might have implica-
tions for adequate treatment but also for outcome. Plenty
of studies are available focusing on one specific syndrome,
but until now only few studies looked at more than one
syndrome in the same population. In geriatric patients,
simultaneous occurrence of sarcopenia and malnutrition
[5, 14] and of sarcopenia and cachexia [15] was described.
In community-dwelling older adults, significant overlaps
between sarcopenia and frailty [16–18] and between
malnutrition and frailty [19] are reported.
To our knowledge, prevalence and concurrent occur-
rence of all four aforesaid syndromes in older inpatients
have not been investigated before. Thus, the aim of the
present study was to assess the prevalence and overlap
of sarcopenia, cachexia, frailty and malnutrition in a
group of older medical inpatients.
Methods
Study design and inclusion criteria
All patients consecutively admitted to the Internal Me-
dical Department 1 of the University Hospital Erlangen
in Germany between August 2014 and November 2014
and fulfilling the following inclusion criteria were asked
to participate in the present cross-sectional study: age
70 years or older, no severe cognitive impairment, ability
to perform Bioelectrical Impedance Analysis (BIA) in a
standing position, no end of life situation and ability to
communicate and answer questions. The study was
approved by the ethics committee of the Friedrich-Alex-
ander-Universität Erlangen-Nürnberg. All participants
signed an informed consent form. Data on patient char-
acteristics and components of tissue loss syndromes
were collected by two trained medical PhD students (SB,
MT) within 72 h of hospital admission.
Assessment of patients’ characteristics
Age, sex, main medical diagnoses and number of drugs
taken were extracted from medical records. Living si-
tuation (alone / with other persons / nursing home) was
asked in a personal interview. Independence in basic
activities of daily living (ADL) was assessed using the
Barthel Index with a maximum of 100 points indicating
complete independency [20]. Depressive symptoms were
screened using the Geriatric Depression Scale (GDS)
[21]. The score ranges from 0 to 15, with 15 points indi-
cating severe depressive symptoms. Cognitive status was
rated with the Mini-Mental State Examination (MMSE)
[22]. A score of 25 or more of 30 possible points indi-
cates normal cognitive status. Comorbidity was assessed
using the Charlson Comorbidity Index (CCI) which
considers the presence of 19 defined diseases [23]. The
highest possible score is 37 points indicating severe co-
morbidity. Lower extremity function was assessed using
the Short Physical Performance Battery (SPPB), com-
prising tests for balance, gait speed (4 m course) and
strength (sit-to-stand, 5 repetitions) [24]. The score
ranges from 0 to 12, with 10 or more points indicating
high physical performance.
Definitions of tissue loss syndromes
Sarcopenia, cachexia, frailty and malnutrition were
assessed according to established consensus definitions
which are widely used.
Sarcopenia was defined according to the consensus
definition of the European Working Group on Sarcope-
nia in Older People (EWGSOP) [10] by presence of low
muscle mass plus either low handgrip strength or/and
poor physical performance defined by slow gait speed.
Frailty was assessed according to Fried et al. [11] by
presence of three or more of the following five criteria:
unintentional weight loss, exhaustion, low physical activ-
ity level, slow gait speed and low handgrip strength.
Cachexia was defined according to Evans et al. [12] by
weight loss in the presence of illness, combined with
three or more of the following five criteria: decreased
handgrip strength, fatigue, anorexia, low FFMI or abnor-
mal biochemistry (high CRP, low Hb or low albumin).
For two participants body weight 12 months ago was not
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available, instead a BMI < 20.0 kg/m2 was considered as
recommended by Evans et al. [12].
Malnutrition was defined in accordance with the ESPEN
Consensus Statement by Cederholm et al. [13]. After
screening for malnutrition using the Mini Nutritional
Assessment short form (MNA-SF) [25], patients who were
at risk of malnutrition or malnourished (12 points) were
further rated. Either the presence of a BMI < 18.5 kg/m2
was categorized as malnutrition (alternative 1) or the
occurrence of unintentional weight loss combined with
either a BMI < 22 kg/m2 or reduced FFMI (alternative 2).
Diagnostic criteria and the respective cut-off values
are summarized in Table 1, assessment of individual
components of the syndromes is described below.
Assessment of components of tissue loss syndromes
Bioelectrical impedance and body weight were measured
using a seca medical Body Composition Analyzer 514
(seca, Hamburg, Germany) in a standing position. Body
height was measured with a stadiometer, and BMI was
calculated. Based on BIA skeletal muscle mass was cal-
culated according to Janssen et al. [26] and divided by
height squared to obtain the skeletal muscle index
(SMI). Fat-free mass was calculated using the equation
by Kyle et al. [27] and divided by height squared to ob-
tain the fat free mass index (FFMI). Patients were asked
for their body weight 12 months ago and for their usual
body weight. The weight change was then calculated by
subtraction from the measured current weight. In the
case of weight loss, patients were additionally asked
whether this was intentional. For the two participants
with missing body weight data from 12months before,
weight change between present and usual body weight
was considered for the definition of weight loss in frailty
and malnutrition. Anorexia was assessed according to
Landi et al. [28] as the presence of decreased food intake
and/or the presence of poor appetite during the last days.
Fatigue was identified using the Functional Assessment of
Chronic Illness Therapy Fatigue Scale (FACIT-F) [29].
The score ranges from 0 to 52 points, with a score of less
than 30 indicating severe fatigue. Exhaustion was identi-
fied according to Fried et al. [11] by two questions from
the Center for Epidemiological Studies–Depression
Scale (CESD-S) [30]. Handgrip strength was measured
with a JAMAR hydraulic hand dynamometer following
the Southampton protocol for adult grip strength
measurement [31]. Physical activity was assessed with the
Minnesota Leisure Time Activities Questionnaire [32].
Cut-off values for low physical activity were < 383 kcal per
week for men and < 270 kcal per week for women.
Albumin, hemoglobin (Hb) and C-reactive protein
(CRP) concentrations were analyzed from fasting blood
samples within hospital laboratory routine.
Data analysis and statistics
Results are presented as median and interquartile range
or relative frequencies. Data were tested for normality
using Kolmogorov-Smirnov test. Due to non-normal
Table 1 Diagnostic criteria of tissue loss syndromes
Sarcopenia (EWGSOP [10]) Frailty (Fried et al. [11]) Cachexia (Evans et al. [12]) Malnutrition (ESPEN [13])
Summary Low SMI + (low grip strength
OR slow gait speed)
≥ 3 of 5 criteria WL +≥ 3 of 5 criteria MNA-SF < 12 + [BMI < 18.5 OR
[WL + (BMI < 22 OR low FFMI)]]
Weight loss – ≥10 pounds unintended
in previous year
> 5% in previous year > 10% unintended in previous
year
BMI [kg/m2] – – < 18.5 / < 22
FFMI [kg/m2] – – < 15 (w)/
< 17 (m)
< 15 (w) /
< 17 (m)
SMI [kg/m2] ≤ 6.75 (w) / ≤10.75 (m) – –
Handgrip strength
[kg]
≤ 17–21 (w) / ≤ 29–32 (m)1 ≤17–21 (w) / ≤ 29–32
(m)1
≤ 17–21 (w) / ≤ 29–32 (m)1 –
Usual gait speed
[m/s]
< 0.8 < 0.65 or < 0.762 – –
Fatigue /
exhaustion
– positive answer to ≥ 1
of 2 questions
FACIT-F < 30 points –
Physical activity
[kcal/week]
– < 270 (w) / < 383 (m) – –
Anorexia – – low intake or poor appetite –
Biochemistry – – CRP > 5.0 mg/L or Hb < 12 g/dL or
albumin < 3.2 g/dL
–
Abbreviations: BW body weight, CRP C-reactive protein, FACIT-F Functional Assessment of Chronic Illness Therapy Fatigue Scale [28], FFMI fat-free mass index, Hb
hemoglobin; m men, SM skeletal muscle index, WL weight loss, w women
1sex- and BMI-specific cut-off value [11]; 2 sex- and height-specific cut-off value [11]
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distribution, the Mann-Whitney U test was used to test
differences in patients’ characteristics between the groups
with and without each tissue loss syndrome for statistical
significance. The Chi-square test was applied to detect
differences between categorical data. In case of a sig-
nificant result, a Post hoc z-test with Bonferroni correc-
tion was applied to locate these differences. Statistical
analysis was performed with SPSS Version 23 (IBM
SPSS Statistics, Chicago, IL). Level of significance was
set at p < 0.05.
Results
Patients’ characteristics
One hundred patients were included. From 1086
patients admitted, 684 had to be excluded because of age
< 70 years, 60 because of inability to perform BIA, 51 be-
cause of severe cognitive impairment, 37 because of end
of life situation/severe illness and 15 patients were not
able to answer questions for other reasons. One hundred
thirty nine patients were unwilling to participate.
Median age of the participants was 76.0 years, 48%
were female, median BMI was 26.6 kg/m2 and 27% were
obese (Table 2). The main diagnoses were gastroentero-
logical (33%) and oncological diseases (31%). Thirty-six
patients were suffering from other diseases: chronic ob-
structive pulmonary disease (n = 6), other disease of the
respiratory tract (n = 6), infection (n = 5), disease of the
circulatory system (n = 5), disease of the blood (n = 5),
endocrine, nutritional or metabolic disease (n = 4), dis-
eases of the genitourinary (n = 3) and other diseases
(n = 2). Median CCI was 1 indicating very low comor-
bidity, nevertheless 59% took 5 or more medications.
93% of patients were completely independent in basic
ADL and 49% had a SPPB score of 10 or more points
reflecting high physical performance.
Table 2 Patients’ characteristics of the total sample and of subgroups of patients with sarcopenia, frailty, cachexia and malnutrition
(% or median [IQR])
All (n = 100) Sarcopenia (n = 42) Frailty (n = 33) Cachexia (n = 32) Malnutrition (n = 15)
Sex
female 48.0 40.5 63.6* 46.7 53.1
Age [years] 76.0 [73.0–79.0] 77.5 [73.0–81.0] 76.0 [73.0–80.5] 76.5 [73.0–79.8] 76.0 [71.0–79.0]
BMI [kg/m2] 26.6 [23.8–30.2] 26.7 [22.7–29.7] 28.7 [23.5–32.1] 25.0 [21.1–29.6]* 21.8 [20.5–23.9]*
BMI > 30 kg/m2 27.0 21.4 30.3 0.0* 18.8
Living situation
Alone 23.0 28.6 21.2 26.7 15.6
With others 76.0 71.4 75.8 73.3 84.4
Nursing home 1.0 0.0 3.0 0.0 0.0
Main diagnosis
Oncological 31.0 33.3 25.0 27.3 43.8
Gastroenterological 33.0 31.0 38.2 30.3 21.9
Other 36.0 35.7 36.8 42.4 34.4
Comorbidity: CCI [points] 1.0 [0.0–2.0] 2.0 [0.0–2.0] 2.0 [0.5–2.5] 2.0 [1.0–3.0]* 2.0 [0.0–2.0]
Number of drugs 6 [3–8]1 7.0 [4.0–8.0]3 7.0 [5.0–8.5]* 7.0 [4.0–9.0]2 5.5 [2.8–7.8]2
Polypharmacy (≥ 5 drugs) 59.01 64.33 84.8* 53.32 68.82
Activities of daily living: Barthel index
Completely independent (100 points) 93.0 90.5 84.8* 93.3 84.4*
Physical performance: SPPB [points] 9.0 [7.0–11.0] 9.0 [6.8–10.3]* 7.0 [4.5–9.0]* 8.5 [4.5–9.8]* 9.0 [7.0–9.0]
Reduced performance (< 10 points) 51.0 66.7* 81.8* 80.0* 75.0*
Cognitive status: MMSE [points] 28.0 [26.0–29.0]2 28.0 [26.0–29.0] 28.0 [26.0–29.0]2 28.0 [26.0–29.0]2 29.0 [28.0–30.0]
Impaired cognition (≤ 24 points) 13.02 14.3 12.12 0 12.52
Depressive symptoms: GDS [points] 2.0 [0.0–3.0] 2.0 [0.0–4.0] 3.0 [1.0–5.5]* 3.0 [1.0–5.0]* 3.0 [1.0–7.0]*
Severe depressive symptoms (≥ 10 points) 2.0 2.4 6.1* 6.7 6.3*
Abbreviations: IQR: interquartile range; BMI: body mass index; CCI: Charlson Comorbidty Index (score range 0–37); SPPB: Short Physical Performance Battery (score
range: 0–12); MMSE: Mini-Mental State Examination (score range: 0–30); GDS: Geriatric Depression Scale (score range: 0–15); MNA-SF: Mini Nutritional Assessment
short form (score range: 0–14); WL, weight loss
14 missing; 2 1 missing; 3 2 missing;
*Significant difference between patients with and patients without the respective syndrome (p < 0.05)
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Prevalence rates of tissue loss syndromes and their
relation to patient characteristics and components of
tissue loss syndromes.
Sarcopenia was present in 42%, frailty in 33%, cachexia
in 32% and malnutrition in 15% of the patients. 10%
had severe sarcopenia (all 3 criteria) and 36%
pre-sarcopenia (low SMI only); 54% were pre-frail (1
or 2 criteria). The prevalence rates of the four syn-
dromes were not significantly different between the
three main diagnostic groups (Table 2). Compared to
patients without the respective syndrome, physical per-
formance was significantly reduced in all syndromes,
and BMI was lower in malnourished and cachectic pa-
tients. Patients with frailty and patients with cachexia
had more often reduced ADLs than those without
these syndromes, and patients suffering from frailty
were significantly more often female and took more
drugs than patients without frailty. BMI was above 30
kg/m2 in nearly one third of frail patients.
Prevalence rates of the components of the four syn-
dromes are presented in Table 3 for the whole group
and for the subgroups of patients with each syndrome.
All single diagnostic criteria of each syndrome were sig-
nificantly more prevalent in patients with the respective
syndrome than in patients without (e.g. low SMI, low
handgrip strength and low gait speed in sarcopenic
patients) (indicated in bold in Table 3). In addition, mal-
nourished patients had significantly more often low
albumin concentrations than non-malnourished, and frail
patients had significantly more often low hemoglobin
values and more often anorexia than non-frail patients. In
cachectic patients, the BMI was significantly more often
reduced than in non-cachectic patients and all except two
had a low SMI. All four syndromes are characterized by
significant weight loss during the last 12months, which
was most pronounced in malnourished and least pro-
nounced in frail patients. By definition all malnourished
and all cachectic patients had weight loss > 5% and all
Table 3 Components of tissue loss syndromes in the total sample and in patients with sarcopenia, frailty, cachexia and malnutrition
(% or median [IQR])
All (n = 100) Sarcopenia (n = 42) Frailty (n = 33) Cachexia (n = 32) Malnutrition (n = 15)
WL in last 12 months [kg] 5.1 [0.7–14.1]1 10.7 [1.8–16.7]*1 9.1 [4.2–16.3]* 14.3 [8.4–17.7*] 17.9 [14.9–21.3]*
WL > 5% in last 12 months 50.01 61.9*1 75.8* 100.0* 100.0*
WL > 10% in last 12 months 28.01 47.6*1 39.4 56.3* 100.0*
WL > 15% in last 12 months 22.01 35.7*1 30.3 43.8* 73.3*
Unintended WL > 10 pounds in last 12 months 36.01 47.6*1 63.6* 81.3* 86.7*
Unintended WL > 10% in last 12 months 24.01 40.5*1 36.4* 56.3* 100.0*
BMI < 18.5 kg/m2 2.0 4.8 3.0 6.3* 13.3*
BMI < 22 kg/m2 14.0 21.4 21.2 31.3* 53.3*
FFMI < 15 (w) / 17 (m) kg/m2 [13] 42.0 21.0 42.4 65.6* 100.0*
SMI ≤6.75 (w) / ≤10.75 (m) [49] 78.0 100.0* 69.7 93.8* 100.0*
Low handgrip strength [11] 50.0 85.7* 75.8* 68.8* 66.7
Gait speed < 0.8 m/s [50] 27.0 38.1* 54.5* 34.4 33.3
Gait speed < 0.65 / 0.76 m/s [11] 18.0 21.4 42.4* 28.1 20.0
Exhaustion [11] 46.0 40.5 84.8* 62.5* 53.3
Severe fatigue (FACIT-F < 30 points) [28] 37.0 35.7 69.7* 59.4* 46.7
Low physical activity [31] 45.0 54.8 87.9* 53.1 40.0
Albumin < 3.2 g/dL 18.0 19.0 24.2 37.5* 40.0*
Hemoglobin < 12 g/dL 48.0 52.4 63.6* 50.0 60.0
CRP > 5 mg/L 73.0 76.2 72.7 87.5* 86.7
Anorexia [27] 51.0 57.1 66.7* 78.1* 66.7
MNA-SF [points] [32] 11.0 [10.0–12.0] 11.0 [8.0–12.0] 10.0 [7.0–11.5]* 9.0 [7.3–11.0]* 8.0 [6.0–10.0]*
MNA-SF – at risk of malnutrition (8–11 points) 48.0 45.2 48.5 59.4 53.3
MNA-SF – malnourished (< 8 points) 11.0 19.0* 27.3* 25.0* 46.7*
Abbreviations: BMI body mass index, CRP C-reactive protein, FACIT-F Functional Assessment of Chronic Illness Therapy Fatigue Scale (score range: 0–52 points),
FFMI, fat-free mass index, IQR interquartile range, MNA-SF Mini Nutritional Assessment Short Form (score range: 0–14); SMI, skeletal muscle index; WL, weight loss
12 missing; Bold: diagnostic criteria of the respective syndrome
*Significant difference between patients with and patients without the respective syndrome (p < 0.05)
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malnourished patients (unintended) weight loss > 10%
in the last 12 months. In patients with each syndrome,
the prevalence of malnutrition according to MNA was
significantly higher compared to those without the
respective syndrome.
Overlap between the tissue loss syndromes
In 63% of patients at least one tissue loss syndrome was
observed: in 32% one, in 11% two, in 12% three and in
8% all four. All syndromes were significantly pairwise as-
sociated, except malnutrition and frailty (Table 4). The
overlap between sarcopenia, cachexia, frailty and malnu-
trition is illustrated in a Venn diagram in Fig. 1. In 19%
of patients, sarcopenia and frailty occurred concurrently,
in 20% frailty and cachexia and in 22% sarcopenia and
cachexia with or without additional other syndromes.
All malnourished patients except one were also cachec-
tic (93%) and 80% of malnourished patients were also
sarcopenic. 53% of malnourished patients were also frail,
and these patients were affected by all four syndromes.
Discussion
To the best of our knowledge this is the first study cov-
ering the four tissue loss syndromes (sarcopenia, frailty,
cachexia and malnutrition) simultaneously in one patient
group. Sarcopenia was the most prevalent syndrome in
42% of older medical inpatients and malnutrition the
least prevalent in only 15%. Frailty and cachexia were
prevalent in about one third respectively. Almost two
thirds of the patients were affected by at least one of
these syndromes and considerable overlap was observed
(Fig. 1). Eight percent had all four syndromes.
The patients were in rather good physical and mental
condition, reflected in complete independence in ADLs
in almost all patients, only few cognitive impairment,
only occasional depressive symptoms and very low co-
morbidity (Table 2). Consequently, we experienced no
difficulties measuring handgrip strength and gait speed
which are reported by others in geriatric populations
[14]. This positive selection is at least partly due to the
inclusion criteria and demands for more comprehensive
data assessment in the future.
Prevalence rates of a specific syndrome are generally
dependent on the applied definition. In recent years,
consensus definitions have been developed for all four
syndromes which are widely used in research and were
also used in the present study. For the assessment of
sarcopenia, the EWGSOP definition [10] was applied
because it combines measures of muscle mass and func-
tion and its relation to poor clinical outcome is well
documented [33]. This definition is well established, and
has previously been used in several studies in older hos-
pitalized patients with reported prevalence rates between
10 and 50% [34–38]. A closer look at the methods used
in these studies reveals that despite using the same ge-
neral definition, different operational procedures were
used, i.e. different methods to determine muscle mass,
and different cut-off values to define reduced muscle
mass and function. Using the same diagnostic criteria as
in our study, Perez-Zepeda et al. [34] reported sarcope-
nia in 40% and Sousa et al. [35] in 37% of older patients,
which is similar to our results.
Frailty was assessed using the definition of Fried et al.
[11], as this definition is most widely used, is focused on
the physical phenotype of frailty and relatively straightfor-
ward to assess. In our study one third of the patients were
found to be frail. This proportion is in the same range as
reported earlier by others using the same definition in
older patient populations [39–41]. Frailty was observed
less often than sarcopenia and only 58% of frail patients
were also sarcopenic (Table 4). This phenomenon, i.e.
much lower prevalence of frailty than of sarcopenia, is also
reported in community-dwelling older adults [16, 18],
although not consistently [17]. The frailty definition
includes reduced functionality – low grip strength as
well as slow gait speed – but is, in contrast to all other
syndromes, not necessarily characterized by reduced
muscle mass [11] which is confirmed in our results.
The most prevalent features of frail patients were
exhaustion and low physical activity in 85 and 88% of
patients, respectively (Table 3).
Cachexia is widely acknowledged as a complex meta-
bolic syndrome observed in chronic diseases associated
with systemic inflammation, but difficult to assess due to
the lack of a clear definition for clinical application. We
operationalized cachexia according to Evans et al. [12]
who included biochemical measures which are regarded
as important parameters of the cachexia syndrome and
found a prevalence of 32% which is almost exactly the
same as reported from palliative care cancer patients
Table 4 Prevalence of other tissue loss syndromes (%) in patients with a specific syndrome
Sarcopenia (n = 42) Frailty (n = 33) Cachexia (n = 32) Malnutrition (n = 15)
Sarcopenia – 57.6* 68.8* 80.0*
Frailty 45.2* – 62.5* 53.3
Cachexia 52.4* 60.6* – 93.3*
Malnutrition 28.6* 24.2 43.8* –
*Significant difference between patients with and patients without the respective syndrome (p < 0.05)
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(age 68 ± 11 years) using the same definition (33%) [42].
No other studies reporting the prevalence of cachexia in
older hospitalized patients were found. This is in accord-
ance with a recent systematic review on the prevalence
of cachexia and malnutrition in older cancer patients
scheduled for chemotherapy, where 24 studies were
identified reporting the prevalence of malnutrition but
no study specifically assessed cachexia [43]. Although
cachexia is typically attributed to cancer [3], it was not
significantly more often observed in patients with a pri-
mary diagnosis of cancer (Table 1). Several components
of the cachexia definition were also present in patients
with other syndromes, e.g. anorexia and low hemoglobin
levels in frail patients and reduced body mass, fat-free
mass and albumin levels in malnourished patients.
Besides the necessary criterion loss of weight, the most
prevalent features in cachectic patients were increased
CRP values and anorexia in more than three quarters of
patients (Table 3).
Malnutrition was assessed according to the ESPEN
definition [13], the first consensus definition with
age-specific cut off values for a low BMI. Since its publi-
cation in 2015, the ESPEN definition was used in a num-
ber of studies [5, 44–46] providing a good basis for
comparison of our own results. Surprisingly, malnutri-
tion, which is acknowledged as a widespread syndrome
in older patients [4], was by far the least prevalent syn-
drome in only 15% of our patients, less than half as fre-
quent as the other syndromes. This prevalence is,
however, in accordance with previous studies using the
ESPEN definition, reporting malnutrition in 11 to 15%
of somewhat younger hospitalized patients (mean ages
between 57 and 62 years) [44–46]. A slightly higher
prevalence of 19% was observed in markedly older pa-
tients (85 ± 6 years) in a post-acute geriatric rehabilita-
tion care unit [5]. In the above mentioned review on
malnutrition and cachexia in older cancer patients, a
wide variation in the prevalence of malnutrition was
reported when using weight loss (8–40%) as well as MNA
(3–42%) as criteria for malnutrition [43]. In our study, the
prevalence of malnutrition according to MNA-SF was
11%, thus in the lower part of this range and even lower
than found by using the ESPEN definition. This may be
explained by the close relation of the MNA to functional-
ity and level of dependence [47] and the low level of
dependence in our patient group (Table 1).
Interestingly, malnutrition according to MNA was
significantly more prevalent not only in patients with
malnutrition according to ESPEN but also in all other
syndromes (Table 3). This might also be due to the func-
tional nature of the MNA. Whereas malnutrition according
to MNA was related to frailty as reported earlier by others
Fig. 1 Overlap of sarcopenia , frailty , cachexia , and malnutrition in older medical
inpatients (n=100)
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[47], malnutrition according to ESPEN was not (Table 4).
This is again explainable by the fact that functional
aspects are included in the MNA whereas the ESPEN
definition is restricted to weight loss and reduced body
mass or fat-free mass. Despite this lacking significance
in the association between malnutrition and frailty,
malnutrition according to ESPEN showed the largest
overlap with the other syndromes (Table 4, Fig. 1). All
malnourished patients except one were also cachectic,
which may be due to the fact that two of the three malnu-
trition criteria – weight loss and low fat-free mass – are
also components of the cachexia definition. Despite com-
pletely different diagnostic criteria, however, 80% of the
malnourished patients were also sarcopenic. Interestingly,
all malnourished patients had a low SMI, probably as a
consequence of the experienced weight loss. Thus, the
large overlap of malnutrition with the other syndromes is
probably caused by the fact that malnutrition is mainly
characterized by wasting which is a central symptom also
of the other syndromes. Half of all patients reported a
weight loss of more than 5% within the last 12months,
and this proportion was significantly higher in all syn-
dromes (Table 3) – also in sarcopenia even though weight
loss is not part of the sarcopenia definition.
Interestingly, many more patients in our study had a
reduced muscle mass (78%) than reported a weight loss,
indicating that muscle mass is often reduced also in
persons who did not experience a significant weight loss.
Even though every other patient experienced weight
loss, more than one quarter of the patients was obese,
and obesity did not preclude the presence of sarcopenia,
frailty or cachexia. In these patients, tissue loss is hidden
behind high body (fat) mass and may easily be over-
looked if no special attention is paid. Obese patients
with one or more of the four syndromes might have
higher risks for cardio-metabolic diseases and physical
disability compared to patients with normal BMI and
these syndromes [48] and thus deserve special attention.
In order to identify these patients, body composition
needs to be measured.
The major strength of the present study is the applica-
tion of consensus definitions and complete information
on all four syndromes in the same patients. Moreover,
all measurements were highly standardized. One limita-
tion of the study is the rather small sample size, which is
however, comparable to previous studies investigating
the overlap of tissue loss syndromes in hospital settings
[5, 14]. Due to hospital equipment, we were forced to
select patients who were able to stand which limits the
generalizability of our results. In addition, 13% of the
initially admitted or 58% of eligible patients had to be
excluded due to their unwillingness to participate,
further restraining generalizability. As these patients did
not consent to any data collection, it is unfortunately
not possible to describe potential differences between
these patients and the study sample. It may be assumed
that a selective participation of less severely impaired
patients also contributed to the high physical and mental
performance of the study sample. Another limitation is
that weight loss was assessed based on participant’s
self-reported body weight 12 months ago and not mea-
sured. In addition, the original definition of weight loss
in the ESPEN malnutrition definition (> 10% of habitual
weight indefinite of time, or > 5% over 3 months [13])
had to be adapted to > 10% weight loss in the previous
year. This might have led to a slight underestimation of
the malnutrition prevalence. Furthermore, the accuracy
of BIA measurements is limited in case of changes in
the amount and distribution of body water.
Conclusion
In the present cross-sectional study, the tissue loss syn-
dromes sarcopenia, frailty, cachexia and malnutrition
and their constituting components were widespread
among older medical inpatients, even though patients
were physically and mentally rather unimpaired. The
syndromes occurred concurrently and were interrelated.
In the light of well-known serious health consequences
of each syndrome, in clinical routine attention should be
paid to the presence of each syndrome, also in obese
patients. In addition, each component of the syndromes
needs particular attention as weight loss, reduced muscle
mass, reduced physical performance and inflammation
are treatable by nutritional support, physical exercise or
anti-inflammatory treatment.
Future studies with larger patient groups and longitu-
dinal design are required to clarify the significance of
single and concurrent occurrence of these syndromes
for clinical outcome and successful therapy. In this con-
text, specific attention should be paid to diagnostic
tools and cut-off values, since prevalence as well as
overlap of the syndromes is largely dependent on the
applied diagnostic criteria.
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